BIOABioAge Labs Inc. Common Stock
9.480USD-11.81%Mkt Cap: 435.10M $P/E: —3d ago
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to iden…
Industry Peers
Drug Manufacturers - Specialty & Generic$65.19BUSDP/E 23.7
$58.06BUSD
$43.98BUSDP/E 20.4
$43.51BUSDP/E 62.2
$29.89BUSDP/E 12.7
$32.12BUSDP/E 12.7
$22.01BUSDP/E 18.4
$18.75BUSD
$15.34BUSDP/E 117.3
$14.67BUSDP/E 26.4
$15.51BUSDP/E 22.3
$11.98BUSD
$10.15BUSDP/E 29.7
$8.66BUSDP/E 19.0
$8.11BUSDP/E 127.2
$7.88BUSD
$6.53BUSDP/E 23.9
$6.24BUSDP/E 37.3
$6.14BUSDP/E 49.0
$6.08BUSDP/E 79.8
| Headline | Source | Time |
|---|---|---|
Older | ||
 BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever. | ||
IInsider Monkey | ||